56 related articles for article (PubMed ID: 38402402)
1. The upregulation and transcriptional regulatory mechanisms of Extra spindle pole bodies like 1 in bladder cancer: An immunohistochemistry and high-throughput screening Evaluation.
Zhang W; Liang ZQ; He RQ; Huang ZG; Wang XM; Wei MY; Su HL; Liu ZS; Zheng YS; Huang WY; Zhang HJ; Dang YW; Li SH; Cheng JW; Chen G; He J
Heliyon; 2024 May; 10(10):e31192. PubMed ID: 38813236
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of apatinib treatment for gastric cancer, hepatocellular carcinoma and non-small cell lung cancer: a meta-analysis.
Xue JM; Astère M; Zhong MX; Lin H; Shen J; Zhu YX
Onco Targets Ther; 2018; 11():6119-6128. PubMed ID: 30288047
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Response Biomarkers of Apatinib in the Treatment of Malignancies in China: A Review.
Tian Z; Niu X; Yao W
Front Oncol; 2021; 11():749083. PubMed ID: 34676173
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide CRISPR screen identifies ESPL1 limits the response of gastric cancer cells to apatinib.
Zhang B; Chen Y; Chen X; Ren Z; Xiang H; Mao L; Zhu G
Cancer Cell Int; 2024 Feb; 24(1):83. PubMed ID: 38402402
[TBL] [Abstract][Full Text] [Related]
5. Paeonol inhibits the malignancy of Apatinib-resistant gastric cancer cells via LINC00665/miR-665/MAPK1 axis.
Li M; Cai O; Yu Y; Tan S
Phytomedicine; 2022 Feb; 96():153903. PubMed ID: 35026514
[TBL] [Abstract][Full Text] [Related]
6. Pan-Cancer analysis and experimental validation identify the oncogenic nature of ESPL1: Potential therapeutic target in colorectal cancer.
Zhong Y; Zheng C; Zhang W; Wu H; Wang M; Zhang Q; Feng H; Wang G
Front Immunol; 2023; 14():1138077. PubMed ID: 37006282
[TBL] [Abstract][Full Text] [Related]
7.
Yu J; Zhang X; Ma Y; Li Z; Tao R; Chen W; Xiong S; Han X
Cancer Biother Radiopharm; 2021 Feb; 36(1):95-105. PubMed ID: 32552008
[No Abstract] [Full Text] [Related]
8. Extra Spindle Pole Bodies-Like 1 Serves as a Prognostic Biomarker and Promotes Lung Adenocarcinoma Metastasis.
Nie Z; Pu T; Han Z; Wang C; Pan C; Li P; Ma X; Yao Y; Zhao Y; Wang C; Jiang X; Ding J
Front Oncol; 2022; 12():930647. PubMed ID: 35814478
[TBL] [Abstract][Full Text] [Related]
9. TWIST1-EP300 Expedites Gastric Cancer Cell Resistance to Apatinib by Activating the Expression of COL1A2.
Yu G; Chen W; Li X; Yu L; Xu Y; Ruan Q; He Y; Wang Y
Anal Cell Pathol (Amst); 2022; 2022():5374262. PubMed ID: 35242497
[TBL] [Abstract][Full Text] [Related]
10. Targeting BCL6 in Gastrointestinal Stromal Tumor Promotes p53-Mediated Apoptosis to Enhance the Antitumor Activity of Imatinib.
Zeng X; Zhao F; Jia J; Ma X; Jiang Q; Zhang R; Li C; Wang T; Liu W; Hao Y; Tao K; Lou Z; Zhang P
Cancer Res; 2023 Nov; 83(21):3624-3635. PubMed ID: 37556508
[TBL] [Abstract][Full Text] [Related]
11. CRISPR activation screening in a mouse model for drivers of hepatocellular carcinoma growth and metastasis.
Zhang B; Ren Z; Zheng H; Lin M; Chen G; Luo OJ; Zhu G
iScience; 2023 Mar; 26(3):106099. PubMed ID: 36843840
[TBL] [Abstract][Full Text] [Related]
12. Extracellular Vesicle-Mediated Transfer of LncRNA IGFL2-AS1 Confers Sunitinib Resistance in Renal Cell Carcinoma.
Pan Y; Lu X; Shu G; Cen J; Lu J; Zhou M; Huang K; Dong J; Li J; Lin H; Song H; Xu Q; Han H; Chen Z; Chen W; Luo J; Wei J; Zhang J
Cancer Res; 2023 Jan; 83(1):103-116. PubMed ID: 36264173
[TBL] [Abstract][Full Text] [Related]
13. Drugging p53 in cancer: one protein, many targets.
Hassin O; Oren M
Nat Rev Drug Discov; 2023 Feb; 22(2):127-144. PubMed ID: 36216888
[TBL] [Abstract][Full Text] [Related]
14. ESPL1 Is a Novel Prognostic Biomarker Associated With the Malignant Features of Glioma.
Liu Z; Lian X; Zhang X; Zhu Y; Zhang W; Wang J; Wang H; Liu B; Ren Z; Zhang M; Liu M; Gao Y
Front Genet; 2021; 12():666106. PubMed ID: 34512713
[TBL] [Abstract][Full Text] [Related]
15. FOXK2 transcriptionally activating VEGFA induces apatinib resistance in anaplastic thyroid cancer through VEGFA/VEGFR1 pathway.
Feng H; Jin Z; Liang J; Zhao Q; Zhan L; Yang Z; Yan J; Kuang J; Cheng X; Qiu W
Oncogene; 2021 Oct; 40(42):6115-6129. PubMed ID: 34489549
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
